Airfinity is pleased to announce Alex Karle’s appointment as Chair of the company. Alex takes on the position having joined as an advisor to the organisation last year.
Alex takes over from J.P. Leschly Neergaard who has been Chair since 2022 after also joining as an advisor in 2018. J.P. is credited with steering Airfinity though intensive growth during the pandemic, securing new investment and opening offices in the US and Japan. J.P. will remain on the board and continue to support the business.
J.P. says “It has been a privilege to chair a company with a strong and relevant mission and incredible talented people on board. Airfinity is on an exciting trajectory and I am delighted to hand over the Chairmanship to Alex Karle who is perfectly qualified to guide and support the company to the next level. I will remain a board member and a happy investor.”
As new Chair, Alex Karle will be focused on continuing our growth journey, enabling us to scale successfully and build our operations in new markets globally. Alex brings more than 15 years of experience in rapidly growing data and analytics businesses, skills and expertise which will support our ambitions to expand the business into new areas with advanced data forecasting and simulations.
He spent five years heading up strategy and M&A for Thomson Reuters’ Life Sciences businesses. He went on to become CEO of Evaluate, a leader in life science consensus forecasts, and oversaw its rapid growth. Alex also acted as a board adviser to Scibite during its successful exit to Elsevier in 2020.
Airfinity’s founder and CEO Rasmus Bech Hansen says, “I’m very grateful for everything J.P. Neergaard has done to build Airfinity into the business it is today and am glad he will remain working with us and supporting our next stage of growth.
“I’m excited to have Alex getting more involved. He has the right skills and expertise to help us scale and continue building the best predictive data and analytics solution for the life sciences industry. Alex will support our mission to provide actionable insights to inform key decisions that can increase the global life span.”